ADMA Biologics Secures $300M Credit Agreement with JPMorgan

ADMA Biologics ( (ADMA) ) has provided an update.

On August 5, 2025, ADMA Biologics entered into a $300 million credit agreement with JPMorgan Chase Bank, which includes a $75 million term loan and a $225 million revolving credit facility. This refinancing replaces existing debt, lowers borrowing costs, and enhances strategic financial flexibility. Additionally, ADMA reported strong financial results for the second quarter of 2025, with a 14% year-over-year revenue increase and significant earnings growth. The company also initiated commercial-scale manufacturing with an FDA-approved process, acquired a new facility to expand its U.S. supply chain, and repurchased $15 million in common stock, positioning itself for accelerated growth in the latter half of 2025 and beyond.

The most recent analyst rating on (ADMA) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on ADMA Biologics stock, see the ADMA Stock Forecast page.

Spark’s Take on ADMA Stock

According to Spark, TipRanks’ AI Analyst, ADMA is a Outperform.

ADMA Biologics’ strong financial performance and optimistic earnings call, which includes raised guidance and strategic initiatives, are the primary drivers of the high stock score. Technical analysis suggests caution, but this is outweighed by the company’s robust financial health and growth prospects.

To see Spark’s full report on ADMA stock, click here.

More about ADMA Biologics

ADMA Biologics, Inc. is a U.S.-based biopharmaceutical company focused on the manufacturing, marketing, and development of specialty biologics. The company operates in the healthcare industry, with a particular emphasis on plasma-derived products and related manufacturing processes.

Average Trading Volume: 3,093,941

Technical Sentiment Signal: Buy

Current Market Cap: $4.53B

For a thorough assessment of ADMA stock, go to TipRanks’ Stock Analysis page.